Leerink Partnrs Analysts Reduce Earnings Estimates for KYTX

Key Points

• Analysts at Leerink Partners have reduced their Q3 2025 earnings estimates for Kyverna Therapeutics from ($0.76) to ($0.86) per share.
• Kyverna Therapeutics reported a quarterly EPS of ($0.97), slightly exceeding the consensus estimate of ($1.00).
• The company receives a buy rating from five research analysts, with an average price target of $15.60.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Equities research analysts at Leerink Partnrs cut their Q3 2025 earnings per share estimates for shares of Kyverna Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($0.86) per share for the quarter, down from their previous forecast of ($0.76). The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.63) EPS, FY2026 earnings at ($3.37) EPS, FY2027 earnings at ($4.03) EPS, FY2028 earnings at ($4.14) EPS and FY2029 earnings at ($3.38) EPS.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.03.

Separately, HC Wainwright upgraded Kyverna Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the company from $4.00 to $5.00 in a report on Tuesday, May 27th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $15.60.

Kyverna Therapeutics Stock Up 2.0%

Shares of KYTX stock opened at $3.54 on Friday. The firm has a 50 day moving average of $3.44 and a two-hundred day moving average of $2.79. The stock has a market capitalization of $153.11 million, a PE ratio of -0.96 and a beta of 3.05. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $8.78.

Institutional Trading of Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KYTX. Peapod Lane Capital LLC acquired a new position in Kyverna Therapeutics in the first quarter valued at $765,000. Gilead Sciences Inc. acquired a new position in Kyverna Therapeutics in the 4th quarter valued at about $15,432,000. Two Sigma Investments LP raised its stake in Kyverna Therapeutics by 47.9% during the 4th quarter. Two Sigma Investments LP now owns 181,654 shares of the company's stock valued at $679,000 after acquiring an additional 58,800 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Kyverna Therapeutics by 2,225.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock worth $1,728,000 after acquiring an additional 442,090 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Kyverna Therapeutics by 53.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company's stock valued at $53,000 after purchasing an additional 4,990 shares during the last quarter. Institutional investors and hedge funds own 18.08% of the company's stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.